

SCIENTIFIC PROGRAM

SESSION LECTURE

No. 41

Cancer Frontier
Room: 301AB

Co-Chairs: Qimin Zhan



Qingyi Wei



Day 2 October 28th (Sunday) 14:00 – 17:00

Time	Speaker	Title
14:00-14:20		Opening speech
14:20-14:40	Qimin Zhan <i>Peking University, China</i>	Race to cancer precision medicine
14:40-15:00	Yeul Hong Kim <i>Korea University College of Medicine, Korea</i>	Korean Cancer Precision Medicine Initiative
15:00-15:20	Jiafu Ji <i>Peking University Cancer Hospital, China</i>	Localization Strategy for Gastric Cancer Treatment in China
15:20-15:40		Q & A
15:40-16:00	Qingyi Wei <i>Duke University, USA</i>	The DCAF4 (DDB1 and CUL4- associated factor 4) Gene and Lung Cancer Risk
16:00-16:20	Ruihua Xu <i>Sun Yat-sen University Cancer Center, China</i>	Progress in the diagnosis and treatment of Gastrointestinal Cancer
16:20-16:40		Q & A
16:40-17:00		Closing remarks



Qimin Zhan

zhanqimin@bjmu.edu.cn

Dr. Zhan was the Chairman of the National Advisory Board for 863 High-Tech plan in the field of biomedical sciences and is the Chief Scientist of the 973 National Fundamental Program. Dr. Zhan's research interest is focused on the molecular pathways involved in the control of cell cycle checkpoint and apoptosis after DNA damage, and the signaling pathways involved in regulation of the maintenance of genomic stability and tumor metastasis.



Yeul Hong Kim

yhk0215@korea.ac.kr

Dr. Kim is primarily interested in the development of new therapies in gastric cancer, colon cancer and other gastrointestinal cancers including pancreatic cancer and biliary cancer. He is actively involved in the Cancer Genomic research for lung and gastrointestinal cancers using circulating tumor DNA. He has served as the President of Asian Clinical Oncology Society from 2016. Currently he is Director of the KMASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, which is a cancer precision medicine project funded from Korea Ministry of Health and Welfare.



Ruihua Xu

xurh@sysucc.org.cn

Vice president of China Anti-cancer Association (CACA), Vice president of Chinese Society of Clinical Oncology (CSCO), Vice president of China Medicinal Biotechnology Association (CMBA), Chairman of Committee of targeted therapy in Oncology, China Anti-Cancer Association, Editor-in-Chief of Chinese Journal of Cancer. Dr. Ruihua Xu specializes in GI medical oncology, mainly engaged in the development of novel drugs and individualized treatment for GI cancer. Several of his innovative achievements have international leading position, including research of metastasis of GI cancer, chemotherapy drug resistance mechanism and optimization of clinical management. The 5-year survival rate of his patients leads international advanced level.



Qingyi Wei

weiqingyi@yahoo.com

Prof. Wei in the Department of Medicine, is Associate Director for Cancer Control and Population Sciences, Co-leader of CCPS and Co-leader of Epidemiology and Population Genomics (Focus Area 1). He is a professor of Medicine and an internationally recognized epidemiologist focused on the molecular and genetic epidemiology of head and neck cancers, lung cancer, and melanoma. His research focuses on biomarkers and genetic determinants for the DNA repair deficient phenotype and variations in cell death.



Jiafu Ji

jijiafu@hsc.pku.edu.cn

Prof. Ji is internationally recognized for his expertise in surgical treatment for gastric cancer and related basic and clinical research. As a distinguished professor of gastrointestinal surgery, he is leading the effort to promote standardization of surgical procedures and development and application of neo-adjuvant chemotherapy for gastric cancer in China. His current research focuses on integrated treatment of gastric cancer and its molecular mechanisms. He is the leading researcher of many domestic and international clinical trials. With unique vision, Prof. Ji also took the lead in constructing the biggest cancer biobank in China.